Morgan Stanley reports that the 1H2023 performance of Dicker Data (ASX:DDR) demonstrates how improving supply chains are benefiting its working capital.

The stability in the computer parts distributor’s working capital provides the company the opportunity to navigate past near-term difficulties.

Shares saw an increase of up to 3.45%, reaching their highest point since September 15 at A$9.9.

Morgan Stanley has decided to maintain its ‘overweight’ rating on the company, raising its price target from A$10 to A$11.

However, the firm notes slowing demand and PC inventory driven unfavorable movements in the working capital as key risks for the company.

The ‘buy’ equivalent is the average rating of brokerages, with a median price target of A$9.7 according to London Stock Exchange Group.

Compared to the 30-day average volume of 182,961 shares, about 128,000 shares were traded.

As of the last closing, the stock is down 6.1% for the year.

Dicker Data (ASX:DDR) is an Australian computer parts distributor.

Shares of Mayur Resources (ASX:MRL) have risen as much as 13% to A$0.175, marking their greatest intraday percentage gain since August 14.

The company reached its peak level since September 26.

The launch of its central lime project’s (CLP) inner rubble core wharf infrastructure has been cited as a reason for the rise.

Situated 25 kilometers north of Papua New Guinea’s capital, the wharf infrastructure is expected to facilitate early barging operations for the transport of goods and materials.

Further, Mayur Resources indicates that the infrastructure could enable the CLP to seize early cash flow prospects in 2024.

Despite the recent gains, the stock recorded an 11.4% drop year to date, up until the last close.

Mayur Resources is a natural resource development company based in Papua New Guinea, specializing in acquisition, exploration, and development of mineral and energy resources.

Morgan Stanley has indicated positive projections for healthcare services provider Ramsay Health Care (ASX:RHC).

The financial services company anticipates improvement in the earnings margin for Ramsay, attributing this to possible reductions in labour supply constraints and the implementation of cost-saving initiatives.

The brokerage has subsequently raised the price target for Ramsay Health Care’s shares from A$49.6 to A$53.6.

An increase of 18% in the FY24E earnings per share (EPS) and a 40% growth in the FY25E EPS are also forecasted.

Additionally, the growth for FY25E is expected to be propelled by improved EBITDAR margins in Australia and France.

This optimism extends to a recovery in France’s earnings margins, with projected underlying EBITDAR margins of 14% in 2H23, increasing by 60bps in FY24E, 130bps in FY25E, and thereafter by 30bps per annum.

Out of 16 analysts reviewing Ramsay Health Care, three have rated the stock as ‘buy’, twelve as ‘hold’, and one as ‘sell’, with a median price target of A$55.95, according to LSEG data.

Year to date, Ramsay Health Care’s shares have declined 20.7% as of the last close.

Ramsay Health Care (ASX:RHC) is a prominent provider of healthcare services.

Shares of Heavy Minerals (ASX:HVY) saw a rise of as much as 26.3% to A$0.120 and is on track for its best day since July 13, assuming gains are maintained.

The industrial minerals miner announced that it has awarded the pre-feasibility study for its garnet mine at Port Gregory, Australia, to mineral sands engineering firm IHC Mining.

The company will consider multiple production profiles to enhance the Net Present Value (NPV) of the project.

The trading volume reached 1.1 million shares, significantly higher than the 30-day average volume of 108,535 shares.

The stock has reached its highest level since September 14 even though it has fallen 36.7% year-to-date as of its last close.

Heavy Minerals (ASX:HVY) is an industrial minerals miner focusing on garnet mining.

Shares of Tombador Iron (ASX:TI1), an Australia-based company, have plunged as much as 27.8% to A$0.013, marking the lowest level since July 2003.

Tombador Iron announced that it would continue to face production constraints in the December 2023 quarter.

The company is awaiting geotechnical advice following the completion and analysis of geotechnical drilling and assessments, leading to current production constraints.

This situation, combined with current sales and production levels, has resulted in increased cost per tonne at the company’s iron ore mine in North East Brazil.

The stock posted its biggest intraday percentage fall since May 2019 with 3.3 million shares exchanging hands as of 0307 GMT, compared to the 30-day average volume of 782,877 shares.

The stock has declined by 30.8% year to date, as of last close.

Tombador Iron (ASX:TI1) is an Australia-based company operating an iron ore mine in North East Brazil.

Shares of biotechnology company CSL (ASX:CSL) increased as much as 1.73%, reaching A$250.61.

This marks their largest gain since August 30.

Analysts at Morgan Stanley opined that the execution of Patient Blood Management (PBM) might neutralize the competitive risk presented by injectafer generics for CSL.

PBM is a method employed in the treatment of surgical patients who necessitate blood transfusion.

The analysts project an earnings per share increase of approximately 16%, subsequently bolstered by opportunities for injectafer within PBS programs.

The brokerage’s 12-month price target for CSL is A$334 per share, 33% above the present level of A$252 per share.

As per LSEG data, the average analysts' rating mirrors a ‘Buy’ suggestion, with their median price target settled at A$325.

About 409,000 shares were traded, compared to the 30-day average volume of 755,322.

As of the last closing, the stock has declined 14.4% YTD.

CSL is a leading company in the biotechnology sector known for its wide range of plasma-derived and recombinant therapies.

BBX Minerals (ASX:BBX) shares rise as much as 15.4% to A$0.030, predicted for its best day since August 22, if these gains are consistent.

The mineral explorer announced receiving positive assay results from an ammonium sulphate leach test conducted in Brazil.

BBX reported that rare earth recoveries are comparable to typical Chinese ionic deposits.

The stock is at its highest level since September 25, however, the company’s stock was down 75% this year, based on last close.

BBX Minerals is a company involved in mineral exploration.

Shares of Nimy Resources (ASX:NIM) experienced an increase of as much as 34.2% to A$0.255.

The stock is headed towards its largest gain since June 8, given the current trending behaviour.

Significantly, the nickel miner announced the identification of considerable nickel-copper sulphides at its first drilling hole at maximum likelihood-expectation maximization (MLEM) conductive plates in its Mons Project, Western Australia.

To expedite assaying, samples have been delivered to Perth.

The stock has reached its highest level since June 28.

There was a transaction of 1.2 million shares, in stark contrast to the 30-day average volume of 107,846 shares.

As per the last closing, the stock was down by 24% Year to Date.

Nimy Resources (ASX:NIM) is a company that specialises in the mining of nickel.

Athena Resources (ASX:AHN) has announced that the previously proposed Byro South JORC drilling program has been temporarily put on hold.

Operations are expected to resume upon initiation of production.

Athena Resources is a mining and exploration company, specializing in the discovery, development, and mining of key metals and minerals.

Pharmaxis (ASX:PXS) has made an announcement regarding the sale of its Mannitol Respiratory business to Arna Pharma.

The sale of the business to Arna Pharma is expected to conclude by the end of October 2023.

As a result of the sale, Pharmaxis expects a decrease in annual core costs.

Excluding external research costs, this will result in a reduction of more than 60% and will save the company over A$14M each year.

Malcolm McComas, the current chair, will step down effective October 3, with Kathleeen Metters, a current director, appointed by the board as chair.

Following the deal, the net exit costs are estimated to be less than A$1M allowing the company to earn product royalties from Arna Pharma.

It has also been indicated that Pharmaxis will change its name to Syntara as part of the restructuring.

Additionally, the board will be reduced in size.

Pharmaxis is a pharmaceutical manufacturing specialist known for its Mannitol Respiratory business.